Cart
sales@molnova.com
AZD5305
CAS No. 2589531-76-8
AZD5305( —— )
Catalog No. M24160 CAS No. 2589531-76-8
AZD5305 is a potent, selective and oral active PARP inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 377 | In Stock |
|
| 25MG | 630 | In Stock |
|
| 50MG | 879 | In Stock |
|
| 100MG | 1190 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD5305
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD5305 is a potent, selective and oral active PARP inhibitor.
-
DescriptionAZD5305 is a potent, selective and oral active PARP inhibitor.
-
In Vitro——
-
In VivoAnimal Model:Female Han Wistar rats with BRCAm xenograft and PDX models (12-13 weeks of age)Dosage:0.01, 0.03, 0.1, and 0.3 mg/kg Administration:Oral administration; daily, for 35 days Result:Had antitumor efficacy in a dose-dependent manner.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2589531-76-8
-
Formula Weight406.48
-
Molecular FormulaC22H26N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:41.67 mg/mL (102.51 mM; Need ultrasonic)
-
SMILESO=C(C1=NC=C(N2CCN(CC3=CC(N4)=C(N=C3)C=C(CC)C4=O)CC2)C=C1)NC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Fluzoparib
fluzoparib is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours.Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)-deficient cells.?
-
SRI-011381
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.
-
KSQ-4279
KSQ-4279 (USP1-IN-1) is an inhibitor of USP1 and PARP, exhibiting anticancer activity. It is utilized in the study of non-small cell lung cancer, osteosarcoma, ovarian, breast, glioblastoma, bladder, uterine, and pancreatic cancers.
